Two PBMs’ pharmacy chiefs tell AIS Health they agree with a new report by the Institute for Clinical and Economic Review (ICER), which finds that several biologic medications to treat uncontrolled moderate to severe asthma may modestly reduce disease exacerbations and improve quality of life. But the analysis also concludes that because the drugs are costly, the entire therapy class would need price discounts of at least 50% to be considered cost-effective.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.